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Abstract Caspase-3 is the main executor of the apoptotic
process. Higher serum caspase-3 concentrations in non-
survivor compared to survivor septic patients have been
found. The objectives of this work (with the increase of sam-
ple size to 308 patients, and the determination of serum
caspase-3 concentrations also on days 4 and 8 of diagnosis
of severe sepsis) were to know whether an association be-
tween serum caspase-3 concentrationss during the first week,
degree of apoptosis, sepsis severity, and sepsis mortality ex-
ists. We collected serum samples of 308 patients with severe
sepsis from eight intensive care units on days 1, 4 and 8 to
measure concentrations of caspase-3 and caspase-cleaved
cytokeratin (CCCK)-18 (to assess degree of apoptosis). End
point was 30-day mortality. We found higher serum concen-
trations of caspase-3 and CCCK-18 in non-survivors com-
pared to survivors on days 1 (p < 0.001), 4 (p < 0.001), and
8 (p < 0.001). We found an association between serum
caspase-3 concentrations on days 1, 4 and 8 of severe sepsis
diagnosis and serum CCCK-18 concentrations (p < 0.001),
SOFA (p < 0.001), serum acid lactic concentrations
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(p < 0.001), and 30-day sepsis mortality (p < 0.001). The new
findings of this work were that an association between serum
caspase-3 concentrations during the first week, apoptosis de-
gree, sepsis severity, and sepsis mortality exists.
Introduction
Severe sepsis leads to burden of health resources and many
deaths annually [1, 2]. Cell death by apoptosis occurs during
sepsis. Apoptosis is initiatedmainly through two pathways, by
death receptors (or extrinsic pathways) or by mitochondrial
contribution (or intrinsic pathways). In both pathways,
caspase-3 is activated and leads to cell death [3–6].
An increase of caspase-3 activity in different body sites in
septic animal models has been found [7–18]. Besides, higher
caspase-3 activity has been found in lymphocytes of septic pa-
tients compared to healthy controls [19–21], in spleen samples
of septic patients (post mortem obtained) comparted to non-
septic patients (obtained from emergent splenectomy due to
bleeding) [22], and in plasma of septic patients compared to
non-septic patients [23]. In addition, another study found higher
serum caspase-3 levels over 72 h in septic patients with de-
creased lactate clearance, and higher mortality rate in those pa-
tients with lower lactate clearance [24]. In addition, we previ-
ously determined serum caspase-3 concentrations in 216 severe
septic patients at the time of diagnosis [25], and an association
between serum caspase-3 concentrations and 30-day mortality
was found. The objectives of this work (with the increase of
sample size to 308 patients, and the determination of serum
caspase-3 concentrations also on days 4 and 8 of diagnosis of
severe sepsis) were to know whether an association between
serum caspase-3 concentrations during the first week, degree
of apoptosis, sepsis severity, and sepsis mortality exists. If those
associations were found, then serum caspase-3 concentration
determination could be proposed to estimate the prognosis of
those patients, and could open interest for research about agents
that modulate caspase-3 activation in those patients.
Methods
This was a multicenter study carried out with 308 severe septic
patients of intensive care units from eight Spanish hospitals: H
General de La Palma (La Palma), HU Insular (Las Palmas de
Gran Canaria), H Quirón (Santa Cruz de Tenerife), HU de
Valencia (Valencia), HU de Canarias (La Laguna), H San
Jorge (Huesca), HU Dr. Negrín (Las Palmas de Gran Canaria),
and HUNuestra Señora de Candelaria (Santa Cruz de Tenerife).
Ethic review boards from each hospital approved the project.
Patients or their legal guardians signed the informed consent.
We included patients with severe sepsis on the basis of the
International Sepsis Definitions Conference [26]. We
excluded patients with human immunodeficiency virus
(HIV), white blood cell count <1000/μL, solid or hematolog-
ical tumor, steroid, immunosuppressive or radiation therapy,
pregnancy, lactation or age < 18 years.
Previously, we determined other circulating biomarkers in
some of those patients [27–31]. In a previous work, we ana-
lyzed serum caspase-3 concentrations in 216 severe septic
patients at the time of diagnosis [25]. In this work, we deter-
mined serum caspase-3 concentrations also on days 4 and 8 of
diagnosis of severe sepsis in 308 patients.
The following variables were collected: age, acute phys-
iology and chronic health evaluation II (APACHE II) score
[32], activated partial thromboplastin time (aPTT), blood-
stream infection, bilirubin, caspase-3, caspase-cleaved
cytokeratin (CCCK)-18, chronic renal failure (defined as
glomerular filtration rate < 60 ml/min/1.73 m2), chronic
obstructive pulmonary disease (COPD), diabetes mellitus,
creatinine, empiric antimicrobial treatment, international
normalized ratio (INR), lactic acid, ischemic heart disease,
leukocytes, microorganism responsible, pressure of arterial
oxygen/fraction inspired of oxygen (PaO2/FIO2), platelets,
sepsis-related organ failure assessment [SOFA] score [33],
site of infection, and sex. We considered mortality at
30 days as the end point.
Serum blood samples at days 1, 4 and 8 were taken to
measure concentrations of caspase-3 and CCCK-18 serum
levels, and were stored at −80 °C until the determination mo-
ment in the Laboratory Department of the Hospital
Universitario de Canarias (La Laguna, Tenerife, Spain).
Enzyme-linked immunosorbent assay (ELISA) assays were
used to measure caspase-3 with Human Caspase 3 Elisa
BlueGene Biotech® kit (Shanghai, China) and CCCK-18
with M30 Apoptosense® ELISA, PEVIVA AB kit
(Bromma, Sweden). For caspase-3, the intra- and inter-assay
coefficients of variation (CV) were <5.6% and <7.9%, respec-
tively, and the detection limit was 0.1 ng/mL. For CCCK-18,
the intra- and inter-assay CV were <10%, and the detection
limit was 25 U/L. Serum concentrations of CCCK-18 levels
were determined to assess degree of apoptosis [27, 34–36].
We used frequencies (and percentages) and chi-square test
to report and compare categorical variables, and medians (and
interquartile ranges) and Mann-Whitney U test to report and
compare continuous variables. Receiver operating character-
istic (ROC) analyses with serum concentrations of caspase-
3 at days 1, 4 and 8, and survival at 30 days were carried out;
and we used the Youden J index to select the prognostic cut-
off value for each day. Kaplan-Meier 30-day survival curves
using cut-off values of serum caspase-3 concentrations (se-
lected according to Youden J index) of 0.22 ng/mL on day
1, 0.16 ng/mL on day 4, and 0.14 ng/mL on day 8 were carried
out. Logistic regression analyses were carried out to determine
whether an association between 30-day mortality and serum
concentrations of caspase-3 on days 1, 4 and 8 exists.
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Table 1 Baseline clinical and
biochemical characteristics of
survivor and non-survivor
patients
Characteristic Survivors
(N = 206)
Non-survivors
(N = 102)
P-
value
Age, median years (p 25–75) 60 (47–69) 65 (55–74) 0.003
APACHE-II score, median (p 25–75) 19 (15–23) 24 (19–29) <0.001
aPTT, median seconds (p 25–75) 32 (28–39) 36 (29–45) 0.01
Bilirubin (mg/dl), median (p 25–75) 0.88 (0.50–1.40) 0.97 (0.50–2.33) 0.22
Bloodstream infection, n (%) 28 (13.6) 16 (15.7) 0.61
Caspase-3, median ng/mL (p 25–75) 0.12 (0.10–0.23) 0.41 (0.23–0.49) <0.001
CCCK-18, median u/L (p 25–75) 299 (242–398) 474 (326–694) <0.001
Chronic renal failure, n (%) 12 (5.8) 13 (12.7) 0.046
COPD, n (%) 28 (13.6) 11 (10.8) 0.59
Creatinine (mg/dl), median (p 25–75) 1.30 (0.80–2.10) 1.66 (1.00–2.80) 0.01
Diabetes Mellitus, n (%) 51 (24.8) 40 (39.2) 0.01
Empiric antimicrobial treatment adequate 0.64
Unknown due to negative cultures, n (%) 105 (51.0) 55 (53.9)
Unknown due to diagnosis by antigenuria, n (%) 15 (7.3) 4 (3.9)
Adequate, n (%) 82 (39.8) 40 (39.2)
Inadequate, n (%) 4 (1.9) 3 (2.9)
INR, median (p 25–75) 1.25 (1.10–1.50) 1.42 (1.15–1.91) 0.004
Ischemic heart disease, n (%) 20 (9.7) 11 (10.8) 0.84
Microorganism responsible
Unknown, n (%) 105 (51.0) 55 (53.9) 0.63
Gram-positive, n (%) 52 (25.2) 24 (23.5) 0.78
Gram-negative, n (%) 49 (23.8) 23 (22.5) 0.89
Fungi, n (%) 4 (1.9) 4 (3.9) 0.45
Anaerobe, n (%) 2 (1.0) 1 (1.0) 0.99
Lactic acid, median mmol/L (p 25–75) 2.00 (1.10–3.50) 3.40 (1.60–6.00) <0.001
Leukocytes, median ×103/mm3 (p 25–75) 14.2 (9.2–18.9) 15.0 (7.1–20.6) 0.96
Pa02/FI02 ratio, median (p 25–75) 180 (123–271) 170 (104–240) 0.17
Platelets, median × 103/mm3 (p 25–75) 197 (130–270) 129 (61–227) <0.001
Sex 0.52
Female, n (%) 67 (32.5) 37 (36.3)
Male, n (%) 139 (67.5) 65 (63.7)
Site of infection 0.95
Respiratory, n (%) 119 (57.8) 57 (55.9)
Abdominal, n (%) 55 (26.7) 28 (27.5)
Urinary, n (%) 12 (5.8) 5 (4.9)
Skin, n (%) 9 (4.4) 5 (4.9)
Endocarditis, n (%) 6 (2.9) 5 (4.9)
Arthritis, n (%) 1 (0.5) 1 (1.0)
CNS, n (%) 4 (1.9) 1 (1.0)
Sodium, median mEq/L (p 25–75) 138 (134–142) 137 (133–142) 0.35
SOFA score, median (p 25–75) 9 (7–11) 11 (9–14) <0.001
Source of sepsis, n (%) 0.59
Community, n (%) 160 (77.7) 78 (76.5)
Nosocomial extra-UCI, n (%) 23 (11.2) 15 (14.7)
Nosocomial intra-UCI, n (%) 23 (11.2) 9 (8.8)
APACHE II acute physiology and chronic health evaluation, aPTT activated partial thromboplastin time,
CCCK caspase-cleaved cytokeratin, COPD chronic obstructive pulmonary disease, INR international normalized
ratio, PaO2/FIO2 pressure of arterial oxygen/fraction inspired oxygen, CNS central nervous system, SOFA sepsis-
related organ failure assessment score
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We used Spearman’s rank coefficient to test the correlation
between serum concentrations of caspase-3, CCCK-18, and
acid lactic, and SOFA score at days 1, 4 and 8. P-values < 0.05
were considered statistically significant, and Bonferroni cor-
rection was applied in multiple comparisons. We carried out
statistical analyses by NCSS 2000 (Kaysville, UT, USA) and
SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Demographic and clinical characteristics in non-survivor
(n = 102) and survivor patients (n = 206) are shown and
compared in Table 1. Statistically significant differences be-
tween non-survivor and survivor patients were not found on
Pa02/FI02 ratio, leukocytes, bilirubin, sex, ischemic heart dis-
ease, COPD, bloodstream infection, site of infection, and mi-
croorganism responsible for sepsis. However, we found that
non-survivors in comparison to survivors had higher rate of
diabetes mellitus and chronic renal failure, and lower platelet
count. In addition, non-survivors had higher lactic acid, age,
INR, aPTT, SOFA score, creatinine, APACHE-II score, serum
caspase-3 concentrations, and serum CCCK-18 concentra-
tions. Besides, non-survivors compared to survivors had
higher serum concentrations of caspase 3 (Fig. 1) on day 1
(p < 0.001), day 4 (p < 0.001), and day 8 (p < 0.001).
Correlations between serum concentrations of caspase 3,
CCCK-18 and acid lactic, and SOFA score during the first
week are shown in Table 2. We found a statistically significant
positive association of serum concentrations of caspase 3 with
serum concentrations of CCCK-18 (p < 0.001) and acid lactic
(p < 0.001), and with SOFA score (p < 0.001) during the first
week.
ROC analyses of serum concentrations of caspase-3 on
days 1, 4 and 8 as well as 30-day mortality prediction are
shown in Table 3 and Fig. 2. We found that serum concentra-
tions of caspase-3 on day 1 (p < 0.001), day 4 (p < 0.001), and
day 8 (p < 0.001) predict 30-day mortality.
Logistic regression analyses are shown in Table 4. We
found an association between 30-day mortality and serum
concentrations of caspase-3 on days 1 (p < 0.001), 4
(p < 0.001) and 8 (p < 0.001) controlling for SOFA and age.
Fig. 1 Serum caspase-3
concentrations on days 1, 4 and 8
in non-survivor and survivor
patients
Table 2 Correlations between serum levels of caspase-3, CCCK-18
and lactic acid, and SOFA score during the first week of severe sepsis
Measured variable Day 1 Day 4 Day 8
CCCK-18 (u/L) r = 0.37 r = 0.25 r = 0.30
P < 0.001 P < 0.001 P < 0.001
Acid lactic (mmol/L) r = 0.26 r = 0.25 r = 0.22
P < 0.001 P < 0.001 P < 0.001
SOFA score r = 0.20 r = 0.21 r = 0.30
P < 0.001 P < 0.001 P < 0.001
CCCK caspase-cleaved cytokeratin, SOFA sepsis-related organ failure
assessment score
P-values < 0.005 are statistically significant after Bonferroni correction
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Kaplan-Meier 30-day survival curves with cut-off values of
serum concentrations of caspase-3 at days 1, 4 and 8 are
shown in Fig. 3. We found that patients with higher serum
concentrations of caspase-3 on days 1 (p < 0.001), 4
(p < 0.001) and 8 (p < 0.001) had higher risk of death.
Discussion
The new findings of this work were that an association
between serum caspase-3 concentrations during the first
week, apoptosis degree, sepsis severity, and sepsis mor-
tality exists.
Previously, higher caspase-3 activity in lymphocytes of
septic patients compared to healthy controls [19–21], in
spleens of septic patients compared to non-septic patients
[22], in plasma of septic patients compared to non-septic pa-
tients [23], and in serum of septic patients with decreased
lactate clearance [24] have been found. In addition, we previ-
ously found higher serum caspase-3 concentrations at time of
severe sepsis diagnosis in 30-day non-survivors than in survi-
vor patients, and an association between serum caspase-3 con-
centrations at severe sepsis diagnosis and 30-day mortality
[25]. Thus, new findings of this work were that 30-day non-
survivors had higher serum caspase-3 concentrations during
the first week than survivor patients, and that there is an asso-
ciation between serum caspase-3 concentrations during the
first week and 30-day mortality.
We found in our previous study that serum caspase-3 levels
at severe sepsis diagnosis could be used as 30-day sepsis mor-
tality prediction biomarker [25]. Thus, another new finding of
this study was that serum caspase-3 levels on days 4 and 8 of
severe sepsis diagnosis also could be used as a 30-day sepsis
mortality prediction biomarker according to the results of re-
ceiver operating characteristic analysis.
In our previous study, we found that an association between
serum concentrations of caspase-3 (as the main executor of
apoptosis) and CCCK-18 levels (as biomarker of degree of
apoptosis) at the moment of severe sepsis diagnosis exists
[25]. Then, another interesting and new finding of this work
is the association between serum concentrations of caspase-3
and CCCK-18 during the first week.
Another new finding of this work was that an association
between serum concentrations of caspase-3 during the first
week and sepsis severity (assess by serum concentration of
acid lactic and SOFA score) exists.
Fig. 2 Receiver operation characteristic curves of serum caspase-3 levels on days 1, 4 and 8 to predict 30-day mortality
Table 3 Receiver operation
characteristic analysis using
serum concentrations of caspase-
3 at day 1, 4 and 8 as predictor of
mortality at 30 days
Measure Day 1 Day 4 Day 8
Cut-off of serum caspase-3 levels >0.22 ng/mL >0.16 ng/mL >0.14 ng/mL
Sensitivity (95% CI) 78 (69–86) 85 (74–93) 93 (81–98)
Specificity (95% CI) 74 (68–80) 62 (55–69) 61 (53–68)
Positive likelihood ratio (95% CI) 3.1 (2.4–3.9) 2.3 (1.8–2.8) 2.4 (1.9–2.9)
Negative likelihood ratio (95% CI) 0.3 (0.2–0.4) 0.2 (0.1–0.4) 0.2 (0.1–0.3)
Positive predicted value (95% CI) 60 (51–69) 41 (33–50) 35 (27–45)
Negative predicted value (95% CI) 87 (82–92) 93 (87–97) 97 (93–99)
CI confidence intervals
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There are mainly two different pathways of cell death by
apoptosis: the mitochondrial (or intrinsic) pathway and the
death receptor (or extrinsic) pathway [3–6]. The intrinsic path-
way could be initiated by reactive oxygen species or by cyto-
kines as interleukin (IL)-1 and IL-6, and could be slowed by
IL-10 (through to the activation of Bcl-2 anti-apoptotic fami-
ly); and afterwards, cytochrome c is released from mitochon-
dria and caspase 3 is activated. The extrinsic pathway is initi-
ated when the TNF ligand superfamily (TNFSF) binds to the
TNF membrane receptors superfamily (TNFRSF), such as
FasL (Apo-1 L or TNFSF-6 or CD95L) binding to Fas
(Apo-1 or TNFRSF-6 or CD95) or TNF-related apoptosis-
inducing ligand (TNFSF-10 or TRAIL) binding to its different
receptors (TNFRSF-10A to D or TRAILR1 to 4); afterwards,
a death signal is generated to cleave pro-caspase-8 generating
caspase-8 that activates caspase-3. After the activation of cas-
pase-3, by either of two pathways, the cell death is initiated.
Cytokeratin-18 protein, that is present in most parenchymal
and epithelial cells, could cleave during apoptosis by caspases
and its CCCK-18 fragments appear afterward in the blood [37,
38]. Thus, we think that the association that we found in our
work between serum concentrations of caspase-3 during the
first week and sepsis mortality could reflect that patients with
higher caspase-3 (main apoptosis executor) have higher de-
gree of apoptosis (with higher serum CCCK-18 concentra-
tions), higher sepsis severity (with higher SOFA score and
higher serum acid lactic concentrations) and sepsis mortality.
In an animal model with septic rats, the caspase inhibitors
administration have reduced apoptosis and mortality rates [7–9];
thus, all those findings could stimulate interest for research about
agents that modulate caspase-3 activation in those patients.
Certain limitations exist in our work, for example, we have
not determined other molecules related to apoptosis activation,
such as Fas, FasL, and Bcl-2. Besides, we have not determined
the degree of apoptosis by other methods, such as annexin-V to
assess membrane alterations or terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) to assess DNA
fragmentation.
Table 4 Multiple logistic
regression analyses to predict
mortality at 30 days
Measure Odds ratio 95% confidence interval p-value
Model: Mortality estimated at day 1
Caspase-3 levels > 0.22 ng/mL on day 1 9.420 5.229–16.972 <0.001
SOFA at day 1 1.171 1.079–1.270 <0.001
Age (years) 1.022 1.001–1.043 0.04
Model: Mortality estimated at day 4
Caspase-3 levels > 0.16 ng/mL on day 4 8.274 3.615–18.940 <0.001
SOFA at day 4 1.187 1.092–1.290 <0.001
Age (years) 1.019 0.994–1.045 0.14
Model: Mortality estimated at day 8
Caspase-3 levels > 0.14 ng/mL on day 8 15.661 4.519–54.276 <0.001
SOFA at day 8 1.189 1.084–1.304 <0.001
Age (years) 1.025 0.996–1.056 0.09
SOFA sepsis-related organ failure assessment
Fig. 3 Kaplan-Meier 30-day survival curves of serum caspase-3 concentrations on days 1, 4 and 8
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Conclusions
The new findings of this work were that an association be-
tween serum caspase-3 concentrations during the first week,
apoptosis degree, sepsis severity, and sepsis mortality exists.
Thus, serum caspase-3 concentration determination could be
proposed to estimate the prognosis of those patients, and could
open the interest for research about agents that modulate
caspase-3 activation in those patients.
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